IMVT stock forecast
Our latest prediction for Immunovant Inc's stock price was made on the Oct. 13, 2023 when the stock price was at 37.41$.
In the short term (2weeks), IMVT's stock price should underperform the market by -4.11%. During that period the price should oscillate between -11.13% and +6.16%.
In the medium term (3months), IMVT's stock price should underperform the market by -7.87%. During that period the price should oscillate between -30.08% and +6.55%.Get email alerts
Create a solid portfolio with IMVT
About Immunovant Inc
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.97$ per share.
The book value per share is 3.27$
Three months stock forecastOct. 13, 2023
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|